NEOGEN CORP (NEOG)

↓ Download CSV

CIK 0000711377 · Nasdaq · In Vitro & In Vivo Diagnostic Substances

  • Sector Manufacturing
  • Incorporated MI
  • Fiscal year ends May 31

In fiscal 2025, NEOGEN CORP reported revenue of $894.66M, down 3.2% from the prior year. The company ran a net loss, with a net margin of -122.1% and a gross margin of 47.1%. It held $3.44B in total assets against $1.37B in total liabilities.

Key ratios (FY2025)

47.1%
Gross margin
-118.6%
Operating margin
-122.1%
Net margin
-52.7%
Return on equity
-3.2%
Revenue growth (YoY)
Metric (FY)2025202420232022202120202019201820172016
Revenue$894.66M$924.22M$822.45M$527.16M$468.46M$418.17M$414.19M$397.93M$358.28M$321.27M
Cost of Revenue$473.29M$460.32M$416.49M$189.63M$168.21M
Gross Profit$421.38M$463.90M$405.95M$243.01M$215.06M$196.28M$191.92M$186.27M$168.92M$153.06M
Operating Income-$1.06B$58.66M$37.52M$58.62M$74.17M$67.52M$68.09M$70.19M$64.94M$56.39M
Net Income-$1.09B-$9.42M-$22.87M$48.31M$60.88M$59.48M$60.18M$63.15M$43.79M$36.56M
EPS (Diluted)$-5.03$-0.04$-0.12$0.45$0.57$0.56$0.57$1.21$0.86$0.72
Total Assets$3.44B$4.55B$4.55B$992.93M$920.19M$797.18M$695.74M$618.01M$528.41M$449.94M
Total Liabilities$1.37B$1.40B$1.42B$105.56M$79.81M$72.00M$57.84M$57.83M$56.65M$45.78M
Shareholders' Equity$2.07B$3.14B$3.13B$887.37M$840.38M$725.18M$637.90M$560.17M$471.76M$404.16M
Cash & Equivalents$129.00M$170.61M$163.24M$44.47M$75.60M$66.27M$41.69M$83.07M$77.57M$55.26M
Operating Cash Flow$58.24M$35.26M$41.03M$68.04M$81.09M$85.88M$63.84M$69.13M$60.27M$35.33M
Capital Expenditures$104.59M$111.42M$65.76M$24.43M$26.71M$24.05M$14.66M$20.95M$14.58M$14.22M
Shares Outstanding216.89M216.48M188.88M108.02M107.12M105.72M104.85M52.15M51.16M50.50M